CD137 is an inducible molecule of the tumor necrosis factor (TNF) receptor superfamily expressed on activated T cells, NK cells and dendritic cells. Our and others' laboratories have demonstrated that CD137 agonistic monoclonal antibodies (mAb) costimulate potent cell-mediated immune responses leading to regression of established tumors in animal models. Our Iong-term goal is to elucidate the mechanisms of the CD137 mAb in immune potentiation, to maximize its therapeutic potential, and to brinq CD137 mAb-based new therapeutics to treat human cancers. We have recently found that CD137 mAb could reverse established tolerance/anergy of T cells in vivo. This may explain, at least in part, its role in overcoming tumor-induced T cell tolerance. Many human cancers express high levels of B7-H1 and/or B7-H4, which are capable of down-regulating T cell immunity. Therefore, the therapeutic effect of CD137 mAb may be compromised. In addition, we believe there are sufficient data at this time to support the development of anti-human CD137 agonistic mAb for future clinical trials of cancer therapy. In this proposal, we will elucidate the mechanisms of CD137 mAb in the reversal of tumor-induced T cell anergy and evaluate the method and approaches to overcome the roles of tumor-associated B7-H1 and B7-H4 in the evasion of tumor immunity as approaches to maximize therapeutic efficacy. Finally, we will establish """"""""humanized"""""""" CD137 mouse model using gene knock-in technology to facilitate the selection of anti-human CD137 mAb for future clinical trials. Our studies will have a direct impact on the future application of CD137 mAb in cancer treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Muszynski, Karen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Zhu, Yuwen; Yao, Sheng; Chen, Lieping (2011) Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34:466-78
Wang, Jun; Zhao, Wenxia; Cheng, Liang et al. (2010) CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice. J Immunol 185:7654-62
Narazaki, Hidehiko; Zhu, Yuwen; Luo, Liqun et al. (2010) CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 115:1941-8
Melero, Ignacio; Martinez-Forero, Ivan; Dubrot, Juan et al. (2009) Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res 15:1507-9
Jeong, Hye-Young; Lee, Youn-Jae; Seo, Su-Kil et al. (2008) Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J Leukoc Biol 83:755-64
Zhu, Yuwen; Zhu, Gefeng; Luo, Liqun et al. (2007) CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109:4882-9
Xu, Yanhui; Tamada, Koji; Chen, Lieping (2007) LIGHT-related molecular network in the regulation of innate and adaptive immunity. Immunol Res 37:17-32
Xu, Yanhui; Flies, Andrew S; Flies, Dallas B et al. (2007) Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood 109:4097-104
Lee, Seung-Jin; Jang, Byeong-Churl; Lee, Soo-Woong et al. (2006) Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580:755-62
Seo, Su-Kil; Seo, Hyoun-Mi; Jeong, Hye-Young et al. (2006) Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 102:222-8